全文获取类型
收费全文 | 2069篇 |
免费 | 131篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 37篇 |
儿科学 | 65篇 |
妇产科学 | 9篇 |
基础医学 | 276篇 |
口腔科学 | 20篇 |
临床医学 | 217篇 |
内科学 | 413篇 |
皮肤病学 | 18篇 |
神经病学 | 106篇 |
特种医学 | 250篇 |
外科学 | 207篇 |
综合类 | 20篇 |
预防医学 | 196篇 |
眼科学 | 110篇 |
药学 | 104篇 |
中国医学 | 2篇 |
肿瘤学 | 194篇 |
出版年
2023年 | 10篇 |
2021年 | 23篇 |
2020年 | 11篇 |
2019年 | 23篇 |
2018年 | 23篇 |
2017年 | 21篇 |
2016年 | 23篇 |
2015年 | 40篇 |
2014年 | 49篇 |
2013年 | 68篇 |
2012年 | 88篇 |
2011年 | 78篇 |
2010年 | 66篇 |
2009年 | 53篇 |
2008年 | 96篇 |
2007年 | 116篇 |
2006年 | 92篇 |
2005年 | 93篇 |
2004年 | 74篇 |
2003年 | 82篇 |
2002年 | 75篇 |
2001年 | 60篇 |
2000年 | 61篇 |
1999年 | 69篇 |
1998年 | 53篇 |
1997年 | 49篇 |
1996年 | 55篇 |
1995年 | 40篇 |
1994年 | 60篇 |
1993年 | 31篇 |
1992年 | 25篇 |
1991年 | 43篇 |
1990年 | 34篇 |
1989年 | 56篇 |
1988年 | 57篇 |
1987年 | 45篇 |
1986年 | 44篇 |
1985年 | 42篇 |
1984年 | 25篇 |
1983年 | 19篇 |
1982年 | 15篇 |
1981年 | 11篇 |
1980年 | 13篇 |
1979年 | 12篇 |
1978年 | 15篇 |
1977年 | 11篇 |
1976年 | 11篇 |
1975年 | 15篇 |
1966年 | 7篇 |
1965年 | 8篇 |
排序方式: 共有2244条查询结果,搜索用时 15 毫秒
1.
SUMMARY A case congenital dislocation of both knees and dislocation of the left hip in an infant whose mother had a chronic amniotic fluid leakage after mid-trimester amniocentesis. 相似文献
2.
J Kantor K Irvine S Abrams P Snoy R Olsen J Greiner H Kaufman D Eggensperger J Schlom 《Cancer research》1992,52(24):6917-6925
We have previously reported the development of a recombinant vaccinia virus vaccine expressing the human carcinoembryonic antigen (CEA) gene, designated rV(NYC)-CEA. This construct has been shown to elicit specific anti-CEA immune responses and an antitumor effect in a murine tumor model. In the studies reported here, the safety and immunogenicity of this recombinant vaccinia virus were evaluated in a rhesus monkey model. Human CEA is a M(r) 180,000 glycoprotein expressed in approximately 90% of gastrointestinal carcinomas and in some breast and non-small cell lung carcinomas. This family also includes normal cross-reacting antigen (NCA). Rhesus monkeys, like humans, have some NCA on the surface of their granulocytes. Eight monkeys were immunized 3 or 4 times by skin scarification with the recombinant CEA vaccine and four monkeys received wild-type vaccinia virus as control. After three vaccinations, all rV(NYC)-CEA-vaccinated animals exhibited a strong anti-CEA antibody response as measured by enzyme-linked immunosorbent assay. The functional ability of these antibodies to mediate lysis of a CEA-bearing tumor cell was demonstrated using human effector cells. This response could be enhanced by interleukin 2. Cellular immunity to CEA was measured by delayed-type hypersensitivity upon intradermal challenge with purified CEA. Only those animals receiving the recombinant vaccine displayed significant anti-CEA responses. Furthermore, peripheral blood mononuclear cells from immunized monkeys were found to proliferate in response to CEA stimulation. All vaccinated monkeys developed local skin irritation at the site of the vaccination, regional lymphadenopathy, and low-grade fevers after immunization. Following immunization with rV(NYC)-CEA, the response was consistent with the usual constitutional symptoms seen with human smallpox virus immunization. Blood counts, differentials, and hepatic and renal chemistries remained normal in all animals throughout the study and for up to 1 year following the primary vaccination. No evidence of immunological cross-reactivity to NCA was found by either a fall in the granulocyte count or analyses for anti-NCA antibodies. Thus, the rV(NYC)-CEA vaccine appears to be safe in rhesus monkeys. The administration of a CEA recombinant vaccine to rhesus monkeys induces both a humoral and a cell-mediated immune response directed against human CEA. 相似文献
3.
高效液相色谱法测定右旋儿茶素血浆浓度及药代动力学参数 总被引:1,自引:0,他引:1
本文建立了体液中右旋儿茶素的RP-HPLC测定方法。采用C_(18)键合相硅胶为填料的固相提取柱进行样品预处理,右旋儿茶素的提取回收率为79.8%.应用二极管阵列检测器对色谱峰纯度进行鉴定。该法精密度好,方法回收率近100%,日内、日间的变异系数为2.4~5.6%,血浓69.6~1160 ng/ml范围内呈线性关系,r=0.9993。家兔静注右旋儿茶素18mg/kg,其药代动力学过程符合二室模型,分布相半衰期为0.129 h,消除相半衰期为1.19h。 相似文献
4.
T C Greiner C P Burns F R Dick K M Henry I Mahmood 《American journal of clinical pathology》1992,98(5):522-525
Congenital dyserythropoietic anemia type II is a rare disorder that is often diagnosed in patients before age 20 years. Patients with this disorder, which is also called hereditary erythroblastic multinuclearity associated with a positive acidified serum lysis test, may have symptoms of iron overload. The purpose of this case report is to alert physicians to consider the diagnosis of congenital dyserythropoietic anemia type II in elderly patients who have anemia and iron overload. 相似文献
5.
Laparoscopic enucleation of a renal cell carcinoma 总被引:1,自引:0,他引:1
R. C. Luciani M. Greiner J. C. Clement A. Houot J. F. Didierlaurent 《Surgical endoscopy》1994,8(11):1329-1331
The purpose of this study was to report on the feasibility of laparoscopic excision of renal cell carcinoma. An 81-year-old female with renovascular disease underwent a laparoscopic excisional operation for a 2-cm tumor localized in the left kidney.Pathological evaluation showed a low-grade tumor without any extension through the renal capsule (grade I Hand Broder, stage I Robson). The postoperative course was uneventful; there was minimal postoperative pain. The patient was discharged home on the sixth day. Laparoscopic excision would appear to be a safe and effective technique in selected cases. 相似文献
6.
P Thum R Greiner H Blattmann A Coray A Zimmermann 《Strahlentherapie und Onkologie》1988,164(12):714-723
The Swiss Institute for Nuclear Research SIN at Villigen is one of the three centres in the world (LAMPF, Los Alamos; TRIUMF, Vancouver) where pion therapy is possible. A dynamic, tumour conforming spot scan technique for the treatment of deep-seated tumours has been in use since November 1981. With this technique with a favorable integral dose distribution, curative irradiation also of advanced tumours in the retroperitoneum and pelvis is possible. Only at SIN, the treatment of non-resectable soft tissue sarcomas with pions is part of the clinical program. Between 1983 and 1985 totally nine patients were treated, 1/9 with three manifestations, 1/9 with palliative intent. In 20 fractions over five weeks (four fractions a week) total doses of 30 to 36 Gy (90% isodose) were applied. In a follow-up period of eleven to 43 months (median 18 months) only 1/10 tumour manifestations treated with greater than or equal to 30 Gy failed locally. The two-year survival rate (Kaplan-Meier) is 56%. Metastases were the cause of death in 3/5 patients, 1/5 heart disease, 1/5 local tumour progression. Even though 9/11 tumours were located in the retroperitoneum or pelvis, no radiogenic morbidity of the bowel was found. These preliminary results stimulate the intensification of this clinical program. 1986 the same number of patients with non-resectable soft tissue sarcomas was treated as in the whole period 1982 to 1985 before. 相似文献
7.
石杉碱甲类似物的研究II.N-甲基吡啶酮石杉碱甲类似物的合成 总被引:4,自引:1,他引:3
石杉碱甲(1)是从中草药石杉属植物千层塔(Lycopodium serratum Thunb.)中分得的一种高效可逆的乙酰胆碱酯酶抑制剂,临床试验证实它对早老性痴呆症有显著疗效。本文报道N-甲基吡啶酮石杉碱甲类似物2和3的合成。2-甲氧基-5-甲氧羰基-11-亚甲基-5,9-甲撑环辛-7-烯并吡啶(9)在乙腈中用三甲基氯硅烷和碘化钠选择性脱保护以定量的产率得吡啶酮10,再用甲醇钠和碘甲烷甲基化得N-甲基吡啶酮11,11经碱性水解,Curtius重排和氨基的脱保护得N-甲基吡啶酮石杉碱甲类似物2。通过类似的途径从中间体2-甲氧基-5-甲氧羰基-7-甲基-11-酮-5,9-甲撑环辛-7-烯并吡啶(14)合成了类似物3。类似物2和3的乙酰胆碱酯酶抑制活性均低于天然石杉碱甲。 相似文献
8.
9.
Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants 总被引:3,自引:0,他引:3
Filler G; Grygas R; Mai I; Stolpe H; Greiner C; Bauer S; Ehrich J 《Nephrology, dialysis, transplantation》1997,12(8):1668-1671
Background: Only few data exist on pharmacokinetics of
tacrolimus in children. Patients: In 1995 and 1996, 14
children (mean age 13 years, range 5-23 years) received tacrolimus after
renal transplantation; 10 of these after biopsy-proven steroid-resistant
rejection (2 with vascular rejection), two for cyclosporin A (CsA)-induced
severe nephrotoxicity, one for untreatable gingival hyperplasia on CsA, and
one child was treated primarily after transplantation because of severe
liver involvement in nephronophthisis. Pharmacokinetic investigations were
performed after establishing a stable maintenance dose with trough levels
in the desired window of 5-12 ng/ml. Results: Mean
follow-up time was 6 months (range 3-25 months). Eleven patients were still
on tacrolimus. Two were discontinued because of severe aggravation of
chronic persistent hepatitis C (one of them also developed diabetes
mellitus),and one patient was subsequently switched to conventional
immunosuppression because of tacrolimus-associated nephrotoxicity. All
tacrolimus levels were measured by a modified assay (MEIA, Tacrolimus,
Abbott) with improved sensitivity. At the time of switch, median serum
creatinine was 234±82 7mgr;mol;l and 6 months after switch
201±99 &mgr;mol/l. All grafts are still functioning. Mean
FK-506 dose was 0.16 mg/kg body weight/day (range 0.036-0.30 mg/kg). Mean
trough level was 7.1±2.6 ng/ml in the morning and
6.5±2.0 ng/ml in the evening. Median time of maximum
concentration (tmax) was 120 min after application, and the mean maximum
concentration (Cmax) was 15.2±6.7 ng/ml. Mean area under the
curve (AUC) was 104±33 ng * h/ml, with a range from 65 to 169 ng
* h/ml. No patient had unsatisfactorily low trough levels during the study.
There was only a weak but significant (P<0.05) correlation between
dose per kg body weight and AUC and, as expected, an excellent correlation
(r2=0.73, P<0.001) between AUC and trough
level. Conclusion: Because of interindividual
variation between patients, therapeutic drug monitoring of tacrolimus is
mandatory. In this study, a daily dose of 0.15 mg/kg was sufficient in most
patients. We recommend the performance of at least one pharmacokinetic
study after establishing stable FK 506 trough levels to ascertain a safe
profile. 相似文献
10.
F Guadagni M Roselli T Amato M Cosimelli E Mannella P Perri M R Abbolito R Cavaliere D Colcher J W Greiner 《Cancer》1991,68(11):2443-2450
Eighty-two patients diagnosed with gastrointestinal (GI) adenocarcinoma were evaluated before and for 26 months after primary tumor resection for the presence of two serum tumor markers: tumor-associated glycoprotein-72 (TAG-72) and carcinoembryonic antigen (CEA). Elevated TAG-72 and CEA serum levels were found preoperatively in 32 (39%) and 34 (41.5%) of the 82 patients, respectively. The percentage of patients with elevated serum levels of either TAG-72 or CEA was 56.1% (46 of 82). Twelve (15%) patients who had normal CEA serum levels had elevated TAG-72 serum levels, and conversely, serum from 14 (17%) patients who were TAG-72 negative were CEA positive. Forty-five of the 82 patients were diagnosed with advanced disease (i.e., Stages C and D for colorectal, Stages III and IV for stomach), and 29 (64.4%) and 26 (57.8%) of those patients had elevated serum levels of TAG-72 or CEA, respectively. Elevated levels of either TAG-72 or CEA, however, were found in sera of 82.2% of patients with advanced GI cancer, which is an increase of 24.4% over the use of CEA antigen alone as a marker of disease. The measurement of both TAG-72 and CEA may improve the diagnosis of patients with GI malignant disease due to the apparent complementary association which exists between these tumor markers. Serum TAG-72 and CEA levels were monitored in 31 patients for varying lengths of time after resection of the carcinoma; 11 patients developed recurrent disease. Sera from nine of 11 (81.8%) of these patients had elevated TAG-72 levels and six of 11 (54.5%) had elevated CEA levels. Tumor marker elevations were observed either before (35 to 166 days) or at the time of diagnosis of recurrence. The elevation of one or both markers correlated with the clinical status in ten of 11 (90.9%) patients with recurrence. In addition, 20 patients who were clinically free of disease after more than 700 days' follow-up had normal serum levels of both TAG-72 and CEA. These findings suggest that the combined use of serum TAG-72 and CEA measurements may improve detection of recurrence in patients with GI cancer and may be useful in the postsurgical management of GI adenocarcinoma patients. 相似文献